GSDME and neoplasm: Most importantly, we observed a significant increase in GSDME cleavage in subcutaneous tumors in the combination therapy group (Figure 9E and P < 0.0001, SGI‐1027 + everolimus vs vehicle; P < 0.01, SGI‐1027 + everolimus vs everolimus or SGI‐1027), suggesting that SGI‐1027 combined with everolimus can promote tumor regression in vivo by inducing pyroptosis.